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Aim: To determine the effects of arsenic trioxide (ATO) and nilotinib (AMN107, Tasigna) alone or in combination on
the proliferation and differentiation of primary leukemic cells from patients with chronic myeloid leukemia in the
blast crisis phase (CML-BC).
Methods: Cells were isolated from the bone marrow of CML-BC patients and were treated with 1 μM ATO and 5
nM nilotinib, either alone or in combination. Cell proliferation was evaluated using a MTT assay. Cell morphology
and the content of hemoglobin were examined with Wright-Giemsa staining and benzidine staining, respectively.
The expression of cell surface markers was determined using flow cytometric analysis. The levels of mRNA and
protein were analyzed using RT-PCR and Western blotting, respectively.
Results: ATO and nilotinib alone or in combination suppressed cell proliferation in a dose- and time-dependent
pattern (P < 0.01 vs. control). Drug treatments promoted erythroid differentiation of CML-BC cells, with a decreased
nuclei/cytoplasm ratio but increased hemoglobin content and glycophorin A (GPA) expression (P < 0.01 compared
with control). In addition, macrophage and granulocyte lineage differentiation was also induced after drug
treatment. The mRNA and protein levels of basic helix-loop-helix (bHLH) transcription factor T-cell acute lymphocytic
leukemia protein 1 (TAL1) and B cell translocation gene 1 (BTG1) were both upregulated after 3 days of ATO and
Nilotinib treatment.
Conclusions: Our findings indicated that ATO and nilotinib treatment alone or in combination greatly suppressed
cell proliferation but promoted the differentiation of CML-BC cells towards multiple-lineages. Nilotinib alone
preferentially induced erythroid differentiation while combined treatment with ATO preferentially induced
macrophage and granulocyte lineage differentiation.
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Chronic myelogenous leukemia (CML) consists of three
distinct clinical stages, the chronic phase (CP), acceler-
ated phase (AP) and blast crisis (BC) phase. The BC
phase is the most aggressive and terminal phase [1]. At
present, CML treatments, especially for patients in the* Correspondence: wangwei220012@163.com
†Equal contributors
Department of Hematology, Southeast Hospital Affiliated to Xiamen
University (the 175th Hospital of Chinese PLA), NO.269, Zhanghua Middle
Road, Zhangzhou, Fujian 363000, China
© 2015 Wang et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.BC phase, are limited. The pathological mechanism of
CML in BC (CML-BC) is unclear; however, cytogenetic
instability, DNA damage, impaired DNA repair, inhibited
cell apoptosis, dysfunctional cell differentiation and drug
resistance have been implicated in this disease [1,2]. Im-
portantly, enhanced proliferative potential as well as dif-
ferentiation arrest are recognized as the predominant
phenotypes of CML-BC [3]. Inducing CML-BC cell dif-
ferentiation in drug therapy may offer a promising ap-
proach for the treatment of CML patients in BC.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ase inhibitor imatinib (STI571) [4] and nilotinib (AMN107,
trade name Tasigna) [5] are approved for the treatment of
CML-AP or CML-BC patients. The second-generation
tyrosine kinase inhibitor nilotinib appears to be effective
and well-tolerated for those who are resistant to imatinib
treatment [6,7]. However, BCR-ABL kinase domain muta-
tions, which can occur before and during nilotinib ther-
apy, have been indicated to affect the clinical efficacy of
nilotinib [8]. Hence, combined drug applications may help
overcome the drug resistance of nilotinib therapy alone.
Recently, the anti-cancer agent arsenic trioxide (ATO) has
been used for the treatment of patients with acute pro-
myelocytic leukemia (APL) [9]. ATO yields complete re-
mission in APL patients possibly through induction of cell
apoptosis and differentiation [10]. In addition, a recent re-
port demonstrated that combined treatment of interferon
with ATO prolonged the survival of rodents with primary
CML [11]. However, the potential effects of ATO and
nilotinib, either alone or in combination, on CML-BC re-
mains unclear.
In this study, we investigated the effects of ATO and nilo-
tinib on the proliferation and differentiation of CML-BC
cells isolated from CML patients in the BC phase. Our
findings may provide basic evidence for understanding the
molecular mechanisms of ATO and nilotinib therapy for
CML patients in the BC phase.
Results
Effects of ATO and nilotinib on cell proliferation
We first analyzed the effects of ATO and nilotinib alone or
in combination on the proliferation of isolated CML-BC
cells. The results demonstrated that ATO and nilotinib
alone or in combination suppressed cell proliferation in a
dose- and time-dependent pattern (P < 0.01 compared
with control) (Figure 1). Compared with an single drugFigure 1 Effects of ATO and nilotinib on cell proliferation.
Cells were treated with 1 μM ATO and 5 nM nilotinib alone or
in combination for 24, 48 or 72 h, respectively. Cell proliferation
was determined using a MTT assay. CML-BC cells were derived
from five patients with CML-BC and data were calculated from
five independent experiments. **P < 0.01 vs. control.treatment, treatment with ATO plus nilotinib significantly
reduced cell proliferation compared to the other groups
(Figure 1) (P < 0.01).
Morphological examination
Using Wright-Giemsa staining, we examined the morph-
ology of cells following ATO and nilotinib treatment. As
shown in Figure 2, control cells were relatively larger in
size and the nuclei/cytoplasm ratio was also higher than
treated cells. Untreated control cells showed round or
oval shapes, chromatin was loosely and non-uniformly
distributed in nuclei, the nucleus was large and clear, and
cytoplasm was stained with blue. Following ATO or niloti-
nib treatment, cell size was greatly decreased. In addition,
chromatin was condensed and the nuclei/cytoplasm ratio
was reduced, suggesting that these cells were at an early
or middle differentiation stage. In the ATO and nilotinib
combination treatment group, cells showed early erythroid
differentiation morphology, and a small proportion of cells
underwent granulocyte differentiation.
Effects of ATO and nilotinib on the hemoglobin content
The cell hemoglobin content following ATO or nilotinib
treatment was evaluated using benzidine staining. ATO
or nilotinib treatment alone dramatically increased the
percentage of benzidine-positive cells, and nilotinib ap-
peared to be more efficient in upregulating the number
of benzidine-positive cells (control, 8.41% ± 0.75%; ATO,
31.43% ± 1.15%; Nilotinib, 42.05% ± 1.69%; P < 0.01 vs.
control) (Figure 3). Although combination treatment with
ATO and nilotinib elevated the percentage of benzidine-
positive cells, the effect was less than nilotinib treatment
alone (ATO+ nilotinib, 34.96% ± 1.12%). These results in-
dicated that ATO and nilotinib treatment could increase
CML-BC hemoglobin content.
Effects of ATO and Nilotinib on the cell surface antigen
expression
We next determined the cell surface antigen expression,
including GPA, CD41, CD11b and CD14, using flow
cytometric analysis. As shown in Figure 4, a 72-h in-
cubation with ATO and nilotinib alone or in combin-
ation significantly induced the level of GPA, erythroid
lineage marker. Nilotinib had the greatest effect on GPA
expression (Control, 17.85% ± 0.74%; ATO, 73.36% ±
1.28%; Nilotinib, 86.34%± 0.52%; ATO+Nilotinib, 85.39%±
1.32%; P < 0.01 vs. control). There was no significant dif-
ference in GPA expression between nilotinib treatment
and ATO plus nilotinib treatment (P > 0.05). Similarly,
ATO and nilotinib alone or in combination elevated the
expression of CD41 and CD11b, which are macrophage
and granulocyte lineage markers (P < 0.05). Combined
treatment was more potent in upregulating CD41 and
CD11b levels as compared with single drug treatment.
Figure 2 Morphological examination of the effects of ATO and nilotinib on cell differentiation. Cells were treated with 1 μM ATO and 5
nM nilotinib alone or in combination for 72 h. The cells were stained with Wright-Giemsa, and cell morphology was examined under light
microscope at 1000x magnification.
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monocyte biomarker CD14 after drug treatment as com-
pared with control (P > 0.05). These findings suggested
that ATO and nilotinib treatment could promote the
erythroid lineage differentiation of CML-BC cells.
Effects of ATO and nilotinib on TAL1 and BTG1 expressions
Finally, we examined the mRNA and protein expres-
sions of TAL1 and BTG1 in cells following differentFigure 3 Effects of ATO and nilotinib on hemoglobin content. Cells w
for 72 h. Then, cell samples were stained with benzidine. (A) The percent
(B) Representative data of benzidine staining (x200 magnification).treatments. The mRNA and protein levels of TAL1
and BTG1 were both upregulated after three days of
ATO and nilotinib treatment, either alone or in com-
bination (Figure 5). However, compared with the
single drug treatments, combined treatment slightly
decreased the expressions of TAL1 and BTG1. These
results imply that TAL1 and BTG1 may be involved
in ATO and nilotinib-mediated erythroid lineage
differentiation.ere treated with 1 μM ATO and 5 nM nilotinib alone or in combination
age of benzidine-positive cells was calculated. **P < 0.01 vs. control.
Figure 4 Effects of ATO and nilotinib on cell surface antigen expression. A: The level of GPA induced by ATO and nilotinib alone or in
combination (P < 0.01 vs. control). B/C: ATO and nilotinib alone or in combination elevated the expression of CD41 and CD11b (P < 0.05).
Combined treatment was more potent in upregulating CD41 and CD11b levels as compared with single drug treatment. D: the expression of
CD14 after drug treatment as compared with control (P > 0.05).
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Although the well-known tyrosine kinase inhibitor ima-
tinib is effective for all three phases of CML, includingCP, AP and BC, the response during advanced stages of
CML are transient [12-15]. Nilotinib is a novel orally
bioavailable inhibitor of the BCR-ABL tyrosine kinase
Figure 5 Effects of ATO and nilotinib on the expressions of
TAL1 and BTG1. Cells were treated with 1 μM ATO and 5 nM
Nilotinib alone or in combination for 72 h. The mRNA (A) and
protein (B) expressions of TAL1 and BTG1 were evaluated by RT-PCR
and Western blotting, respectively. β-actin was used as an internal
control, and representative data were presented. (A) 1, Control; 2,
Nilotinib treatment alone; 3, ATO treatment alone; 4, Nilotinib + ATO.
(B) 1, Control; 2, ATO treatment alone; 3, Nilotinib treatment alone;
4, Nilotinib + ATO.
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imatinib [16]. At present, nilotinib is used for imatinib-
refractory CML [17]. However, the response to nilotinib
therapy alone is limited, and thus combined drug therapy
may be needed to avoid resistance. In the present study,
we determined the influences of nilotinib and ATO, either
alone or in combination, in cultured cells isolated from
CML-BC patients.
CML-BC involves the accumulation of primitive
hematopoietic cells arrested at an early stage of differen-
tiation. In the patients in this study, a great proportion of
cells in were in the early differentiation stage. Administra-
tion of ATO and nilotinib, alone or in combination, sig-
nificantly suppressed cell proliferation but promoted
erythroid differentiation and granulocyte differentiation.
These findings are consistent with our previous study,
which showed that nilotinib induced erythroid differen-
tiation [18]. ATO is an anti-leukemic agent that leads
to growth suppression and apoptosis induction CML
K562 and human leukemia HL60 cells [19-21]. Our
preliminary experiments demonstrated that a low dose
of ATO (0.5-1 μM) induced differentiation of CML-BC
cells, while ATO at a concentration over 1 μM dramat-
ically inhibited cell growth and promoted cell apop-
tosis. In accordance with our findings, Miller et al.
reported that the effects of ATO on K562 cells was
dose dependent [22]. These findings provide further
evidence of the efficiency of ATO and nilotinib insuppressing proliferation and promoting erythroid dif-
ferentiation of CML-BC cells.
In order to understand the underlying mechanism of
ATO and nilotinib-induced erythroid differentiation of
CML-BC cells, TAL1 and BTG1 expressions were de-
termined. TAL1 gene, also known as SCL or TCL5,
expression has been identified during the differentiation
of erythroid, megakaryocytic, and basophilic lineages
[23]. The production of erythroid and myeloid cells is dra-
matically decreased in TAL1 silenced human hematopoietic
cells [24]. In K562 cells, TAL1 knockdown suppressed
erythroid differentiation [25]. In addition, Aplan et al.
reported that overexpression of TAL1 in K562 cells in
creased the rate of spontaneous (i.e. in the absence of
an inducer) erythroid differentiation [26]. In this study,
ATO and nilotinib treatment promoted the erythroid
differentiation of CML-BC cells and accompanied
increased TAL1 expression. These evidences suggest
that TAL1 may be a positive regulator of erythroid
differentiation.
BTG1 serves as a Forkhead box, class O 3a (FoxO3a)
target gene in erythroid differentiation [27]. Increased
BTG1 expression has been observed in erythroid pro-
genitors during erythroid differentiation [27]. In our pre-
vious study, we showed that FoxO3a activation might
promote erythroid differentiation of CML-BC cells via
down-regulating TAL1 expression [18]. In this study,
increased BGT1 and TAL1 levels were detected in
CML-BC cells following 72 h of nilotinib treatment.
This discrepancy might be due to the prolonged nilo-
tinib incubation (5 d [18] vs. 3 d) and/or increased drug
dose (50 nM [18] vs. 5 nM) in our previous study. It is
possible that TAL1 expression is upregulated during early
erythroid differentiation, but downregulated during late
stages of differentiation. Besides, the efficiency of ATO in
increasing TAL1 and BTG1 expression appears to be less
potent than that of nilotinib.
Here, we observed a synergistic effect of ATO and
nilotinib treatment in suppressing CML-BC cell prolifer-
ation. Although ATO and nilotinib, alone or in combin-
ation, could induce the differentiation of CML-BC cells
into multiple lineages, including erythroid, macrophage
and granulocyte lineages, erythroid differentiation seemed
to predominate. Interestingly, ATO and nilotinib did not
have a synergistic effect in inducing erythroid differenti-
ation. However, combined therapy showed increased effi-
cacy in promoting macrophage and granulocyte lineage
differentiation.
Collectively, our present study demonstrated that
ATO and nilotinib, alone or in combination, suppressed
proliferation and promoted differentiation, especially
erythroid differentiation, of CML-BC cells. Our data
may provide basic evidence for the clinical chemother-
apy of CML patients in BC.
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Reagents
ATO was purchased from Beijing SL Pharmaceutical Co.,
Ltd in Beijing, China. RPMI-1640 culture medium and
fetal bovine serum (FBS) were obtained from GIBCO,
Life Technologies (Carlsbad, CA, USA). The First Strand
cDNA Synthesis Kit and mouse anti-human monoclo-
nal primary antibodies against CD41, GPA and CD11b
were bought from Biolegend (San Diego, CA, USA).
Mouse anti-human monoclonal primary antibodies
against TAL1 and BTG1 were purchased from Santa
Cruz Biotechnology (Dallas, Texas, USA). All of the other
reagents were obtained from Sigma-Aldrich (St. Louis,
MO, USA) unless stated.
Cell culture
CML-BC cells were derived from five patients with
CML-BC in the No. 175 PLA Hospital of China. CML-BC
was diagnosed based on the bone marrow smear and
philadelphia chromosome analysis. Bone marrow mono-
nuclear cells were isolated by density centrifugation
(20 min at 500 g) using lymphocyte separation medium.
The middle layer mononuclear cell samples were washed
three times with phosphate buffer solution (PBS) and re-
suspended with culture medium containing 10% FBS and
1% antibiotics. The single-cell suspension was adjusted to
an appropriate density and seeded onto 96-well plates at a
density of 5–6 cells/well. After 7–10 days of in vitro cul-
ture, the well with single clone formation was sub-cloned.
This procedure was repeated for three to five times until
the positive rate reached 100%.
Experimental assignment
Cells were randomly divided into four groups with three
wells in each group. Control cells were maintained with
RPMI 1640 culture medium. In the ATO and nilotinib
groups, cells were treated with 1 μM ATO and 5 nM
nilotinib, respectively. In the ATO + nilotinib group, cells
were incubated with 1 μM ATO plus 5 nM nilotinib.
Evaluation of cell proliferation
To evaluate cell proliferation, a 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay was used.
Cells were seeded onto a 96-well plate at a density of 3 ×
103 cells/well. After seeding, cells were treated with
200 μL of culture medium containing ATO, nilotinib or
ATO plus nilotinib. Control cells were incubated with the
same volume of culture medium. After 24-, 48-, or 72-h of
incubation at 37°C in a 5% CO2 incubator, 20 μL of MTT
(5 mg/mL) was added to each well. After a subsequent 4 h
of incubation, the medium was removed and 150 μL of di-
methyl sulfoxide (DMSO) was added to each well to re-
suspend the MTT metabolic product. The absorbance ofthe dissolved formazan was measured at 570 nm using a
scanning microplate spectrophotometer.
Wright-Giemsa staining
Cells were collected by centrifugation, and then cell
smears were prepared. After fixation in methanol-glacial
acetic acid solution for 10 min, cells were stained with
Wright-Giemsa for 1 min and then washed with PBS.
Cell samples were dried in air, and the cell morphology
was examined under light microscope.
Benzidine staining
A total of 0.5 mL of cell suspension was mixed with
14 μL of benzidine dye and 0.15 μL of 30% hydrogen
peroxide. After 5 min, 0.15 μL of 5% nitroso iron sodium
hydride was added into the mixture. After a 10–15 min
incubation, cells were examined under a phase contrast
microscope (Motic AE30). The blue-brown cells contain-
ing hemoglobin were identified as positive cells, and other
cells were recognized as negative cells. A total of 300 cells
were counted, and the percentage of positive cells was cal-
culated from three independent experiments.
Cell surface antigen
The expression of cell surface antigen was evaluated by
flow cytometric analysis. Briefly, after three days of drug
treatment, cells were collected by centrifuging at
1,500 rpm for 5 min. The supernatant was discarded and
cells were washed twice with cold PBS. The cell number
was adjusted to 0.1-1 × 106 cells. For each experimental
group, cell samples were divided into two tubes contain-
ing 50 μL of cell sample each. One tube was used to
evaluate cell surface antigen and the other was used as
an isotype control. To assess the expression of specific
cell surface antigen, cells were incubated with primary
antibody against target antigen at 4°C for 60 min. In
the isotype control group, cells were incubated with a
fluorescein-labeled isotype control antibody under the
same incubation conditions. Samples were acquired with
a Partec CyFlow Space flow cytometer (Partec GmbH,
Germany), and data were analyzed using WinMDI version
2.9 software.
Reverse transcription polymerase chain reaction (RT-PCR)
analysis
After three days of drug treatment, total RNA was ex-
tracted from cells using Trizol reagent. cDNA was syn-
thesized according to the instructions of the First Strand
cDNA Synthesis Kit. PCR amplification was performed
on the BTG1 gene upstream primer (5′-CTG CAG ACC
TTC AGC CAG AG-3′) and downstream primer (5′-
GGG TCA ACC CAG AGT GTG AG-3′), TAL1 gene
upstream primer (5′-TTC GTG AGC CCC ATC TTC
AC-3′) and downstream primer (5′-ACA GCC ACA
Wang et al. Cancer Cell International  (2015) 15:10 Page 7 of 8GGC TTA GGA AG-3′), and β-actin gene upstream pri-
mer (5′-CAC ACA GGG GAG GTG ATA GC-3′) and
downstream primer (5′-GAC CAA AAG CCT TCA
TAC ATC TCA-3′). The PCR reaction included 10 μL
of PCR Master mix, 1 μL of each of the upstream and
downstream primers, 4 μL of template cDNA, and 6 μL
of ddH2O in a total volume of 20 μL. The PCR reactions
started with an initial denaturation at 94°C for 2 min,
followed by 28 cycles of 94°C for 30 s, 55°C for 30 s, and
an elongation step of 70°C for 2 min. After gel electro-
phoresis in 1.5% agarose, ethidium bromide-stained bands
were visualized with ultraviolet transillumination.
Western blotting
Total protein was extracted from cells following drug
treatment for three days using lysis buffer supplemented
with phenylmethylsulfonyl fluoride (PMSF). After centri-
fuging at 12,000 rpm for 5 min, the supernatant was col-
lected and the protein concentration was measured
using a Bradford assay. Equal amount of protein extract
was separated by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE), transferred to a PVDF
membrane, blocked for 1 h, and then incubated with pri-
mary antibodies at room temperature for 1 h. The pri-
mary antibodies, including anti-BTG1 (1: 200 dilution),
anti-TAL1 (1: 200 dilution) and anti-β-actin (1: 4000 di-
lution) antibodies, were diluted in Tris buffered saline
plus Tween-20 (TBS-T). After washing with TBS-T,
membranes were incubated with a secondary antibody
for 1 h. Immunobands were visualized using an ECL kit
(Xiamen Lulong Biotech Co., Ltd., Xiamen, China). The
housekeeping protein β-actin was used as an internal
loading control.
Statistical analysis
Data were analyzed by SPSS17.0 software and presented
as means ± standard deviation (SD). Statistical significance
between control and sample groups was determined using
Student t-tests. P < 0.05 or 0.01 was recognized as statisti-
cally significant.
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